3,5-dihydroxyphenylglycine has been researched along with am 281 in 1 studies
| Studies (3,5-dihydroxyphenylglycine) | Trials (3,5-dihydroxyphenylglycine) | Recent Studies (post-2010) (3,5-dihydroxyphenylglycine) | Studies (am 281) | Trials (am 281) | Recent Studies (post-2010) (am 281) |
|---|---|---|---|---|---|
| 301 | 1 | 61 | 104 | 0 | 39 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ano, M; Hashimotodani, Y; Kano, M; Ohno-Shosaku, T; Takeda, S; Tsubokawa, H | 1 |
1 other study(ies) available for 3,5-dihydroxyphenylglycine and am 281
| Article | Year |
|---|---|
Endocannabinoid signalling triggered by NMDA receptor-mediated calcium entry into rat hippocampal neurons.
Topics: Animals; Animals, Newborn; Calcium Channels; Calcium Signaling; Cannabinoid Receptor Modulators; Cells, Cultured; Chelating Agents; Dose-Response Relationship, Drug; Egtazic Acid; Endocannabinoids; Excitatory Amino Acid Agonists; Glycine; GTP-Binding Protein alpha Subunits, Gq-G11; Hippocampus; Inhibitory Postsynaptic Potentials; Lipoprotein Lipase; Morpholines; Muscarinic Agonists; N-Methylaspartate; Neurons; Oxotremorine; Phospholipase C beta; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Receptors, Metabotropic Glutamate; Receptors, Muscarinic; Receptors, N-Methyl-D-Aspartate; Resorcinols | 2007 |